Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13741538 | 0.84 | L3MBTL1 (0.32) | KDM4ELMNAPKML3MBTL1 | |
| SCHEMBL13272289 | 0.83 | ABCB11 (0.30) | ABCB11 | |
| SCHEMBL13741310 | 0.83 | NCEH1 (0.38) | KDM4ELMNA | |
| SCHEMBL13740695 | 0.81 | KDM4E (0.40) | KDM4ELMNAPKML3MBTL1 | |
| SCHEMBL13272290 | 0.81 | ABCB11 (0.32) | ABCB11 | |
| SCHEMBL10013346 | 0.81 | ABCB11 (0.35) | ABCB11 | |
| SCHEMBL13740927 | 0.77 | IDO1 (0.40) | LMNAPKML3MBTL1 | |
| SCHEMBL13740928 | 0.75 | ATM (0.43) | LMNAL3MBTL1 | |
| SCHEMBL13741535 | 0.75 | TSHR (0.49) | — | |
| SCHEMBL30543939 | 0.75 | ABCB11 (0.34) | KDM4EABCB11L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197844-A1 | Demethylpenclomedine Analogs and Their Use as Anti-Cancer Agents | DEKK-TEC, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197844-A1 | Demethylpenclomedine Analogs and Their Use as Anti-Cancer Agents | MCL1, DNMT1, MYC | KDM4E 42/4885LMNA 1636/4885PKM 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.